Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 17;377(7):613-622.
doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28.

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

Daniel L Rolnik  1 , David Wright  1 , Liona C Poon  1 , Neil O'Gorman  1 , Argyro Syngelaki  1 , Catalina de Paco Matallana  1 , Ranjit Akolekar  1 , Simona Cicero  1 , Deepa Janga  1 , Mandeep Singh  1 , Francisca S Molina  1 , Nicola Persico  1 , Jacques C Jani  1 , Walter Plasencia  1 , George Papaioannou  1 , Kinneret Tenenbaum-Gavish  1 , Hamutal Meiri  1 , Sveinbjorn Gizurarson  1 , Kate Maclagan  1 , Kypros H Nicolaides  1
Affiliations
Free article
Randomized Controlled Trial

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

Daniel L Rolnik et al. N Engl J Med. .
Free article

Abstract

Background: Preterm preeclampsia is an important cause of maternal and perinatal death and complications. It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia.

Methods: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 women with singleton pregnancies who were at high risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. The primary outcome was delivery with preeclampsia before 37 weeks of gestation. The analysis was performed according to the intention-to-treat principle.

Results: A total of 152 women withdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the aspirin group and 822 in the placebo group. Preterm preeclampsia occurred in 13 participants (1.6%) in the aspirin group, as compared with 35 (4.3%) in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74; P=0.004). Results were materially unchanged in a sensitivity analysis that took into account participants who had withdrawn or were lost to follow-up. Adherence was good, with a reported intake of 85% or more of the required number of tablets in 79.9% of the participants. There were no significant between-group differences in the incidence of neonatal adverse outcomes or other adverse events.

Conclusions: Treatment with low-dose aspirin in women at high risk for preterm preeclampsia resulted in a lower incidence of this diagnosis than placebo. (Funded by the European Union Seventh Framework Program and the Fetal Medicine Foundation; EudraCT number, 2013-003778-29 ; Current Controlled Trials number, ISRCTN13633058 .).

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

Associated data